GSK

GSK wins $235 million from Teva in Coreg patent trial
GSK wins $235 million from Teva in Coreg patent trial
Reuters
GSK
Teva Pharmaceutical
Coreg
patents
chronic heart failure
Flag link:
GSK’s Bexsero, Shingrix to pass $1B sales mark by 2022: report
GSK’s Bexsero, Shingrix to pass $1B sales mark by 2022: report
Fierce Pharma
GSK
Bexsero
Shingrix
vaccines
shingles
meningitis B
Flag link:
GSK's new pharma head to join in September after AstraZeneca tussle
GSK's new pharma head to join in September after AstraZeneca tussle
Yahoo/Reuters
GSK
AstraZeneca
Luke Miels
Flag link:
GSK uses priority voucher to file HIV combo
GSK uses priority voucher to file HIV combo
BioPharma Dive
GSK
priority review
HIV
ViiV
Flag link:
ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead
ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead
Endpoints
GSK
ViiV
HIV
Flag link:
Pfizer’s Trumenba to challenge GlaxoSmithKline's Bexsero with EU nod
Pfizer’s Trumenba to challenge GlaxoSmithKline's Bexsero with EU nod
Fierce Pharma
Pfizer
Trumenba
GSK
Bexsero
Europe
vaccines
meningococcal B
Flag link:
7 Things You Didn't Know About Gilead Sciences, Inc.
7 Things You Didn't Know About Gilead Sciences, Inc.
Motley Fool
Gilead Sciences
GSK
cash flow
IPOs
Warren Buffett
Flag link:
GlaxoSmithKline's New CEO Is Off to a Good Start
GlaxoSmithKline's New CEO Is Off to a Good Start
Motley Fool
GSK
Pharma CEOs
Emma Walmsley
Flag link:
Gilead needs to best Glaxo with bictegravir
Gilead needs to best Glaxo with bictegravir
EP Vantage
Gilead Sciences
GSK
bictegravir
Dolutegravir
HIV
Flag link:
AstraZeneca throws a monkey wrench in new GSK CEO’s first hiring decision, suing Luke Miels
AstraZeneca throws a monkey wrench in new GSK CEO’s first hiring decision, suing Luke Miels
Endpoints
GSK
Pharma CEOs
Emma Walmsley
AstraZeneca
Luke Miels
Flag link:
GlaxoSmithKline aims for the whole consumer-health shebang with $10.3B Novartis JV buyout
GlaxoSmithKline aims for the whole consumer-health shebang with $10.3B Novartis JV buyout
Fierce Pharma
consumer health
M&A
GSK
Novartis
Flag link:
Glaxit: Flagging a looming threat from Gilead and a weak pipeline, Neil Woodford is giving up on GSK and pulling out
Glaxit: Flagging a looming threat from Gilead and a weak pipeline, Neil Woodford is giving up on GSK and pulling out
Endpoints
Gilead Sciences
GSK
ViiV
Flag link:
Glaxo scores again as FDA strikes down would-be Advair copycats Hikma, Vectura
Glaxo scores again as FDA strikes down would-be Advair copycats Hikma, Vectura
Fierce Pharma
GSK
FDA
Advair
Hikma
Vectura
Flag link:
GlaxoSmithKline looks for Breo boost with landmark real-world asthma study
GlaxoSmithKline looks for Breo boost with landmark real-world asthma study
Fierce Pharma
GSK
Breo Ellipta
asthma
clinical trials
Flag link:
Here's What Wiped $3 Billion Off GlaxoSmithKline's Market Cap in April
Here's What Wiped $3 Billion Off GlaxoSmithKline's Market Cap in April
Motley Fool
GSK
Advair
Flag link:
Look out, Glaxo: Advair is Express Scripts' next big cost-savings target
Look out, Glaxo: Advair is Express Scripts' next big cost-savings target
Fierce Pharma
GSK
Advair
Express Scripts
drug pricing
asthma
COPD
Flag link:
How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 1Q17?
How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 1Q17?
Market Realist
GSK
earnings
Flag link:
How Far Into the Drug Pipeline Should the FTC Reach?
How Far Into the Drug Pipeline Should the FTC Reach?
TheStreet.com
FTC
GSK
Novartis
BRAF inhibitor
MEK inhibitor
melanoma
Array Biopharma
M&A
Flag link:
New GlaxoSmithKline CEO wants fewer, bigger new drug launches
New GlaxoSmithKline CEO wants fewer, bigger new drug launches
Yahoo/Reuters
GSK
Pharma CEOs
Emma Walmsley
drug launches
Flag link:
GlaxoSmithKline’s 1Q17 Earnings: Analysts’ Estimates
GlaxoSmithKline’s 1Q17 Earnings: Analysts’ Estimates
Market Realist
GSK
earnings
Flag link: